PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma-Reference-Cited by-同舟云学术

PD-L1-expressing natural killer cells predict favorable prognosis and response to PD-1/PD-L1 blockade in neuroblastoma

Published:2023-12 Issue:1 Volume:13 Page:
ISSN:2162-402X
Container-title:OncoImmunology
language:en
Short-container-title:OncoImmunology

Author:

Song Mengjia¹²^ORCID,Huang Yue¹³,Hong Ye¹²,Liu Juan¹²⁴,Zhu Jia¹²,Lu Suying¹²,Wang Juan¹²,Sun Feifei¹²,Huang Junting¹²,Xu Jiaqian¹²⁴,Tang Yan¹⁵,Xia Jian-Chuan¹⁵^ORCID,Zhang Yizhuo¹²

Affiliation:

1. Collaborative Innovation Center for Cancer Medicine, State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research Center for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China

2. Department of Pediatric Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China

3. Department of Medical Oncology, The Second Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

4. Department of Pediatric Oncology, The Fifth Affiliated Hospital of Guangzhou Medical University, Guangzhou Medical University, Guangzhou, China

5. Department of Biotherapy, Sun Yat-sen University Cancer Center, Guangzhou, China

Funder

National Key Research and Development Program of China

the National Scientific Foundation of China

China Postdoctoral Science Foundation

Basic and Applied Basic Research Project of Guangzhou, Guangdong province, China

Basic and Applied Basic Research Project of Guangdong province, China

Publisher

Informa UK Limited

Subject

Oncology,Immunology,Immunology and Allergy

Link

https://www.tandfonline.com/doi/pdf/10.1080/2162402X.2023.2289738

Reference33 articles.

1. Harnessing natural killer cells for cancer immunotherapy: dispatching the first responders

2. Neuroblastoma

3. Anti-GD2 synergizes with CD47 blockade to mediate tumor eradication

4. Interleukin 2 with anti-GD2 antibody ch14.18/CHO (dinutuximab beta) in patients with high-risk neuroblastoma (HR-NBL1/SIOPEN): a multicentre, randomised, phase 3 trial

5. A Paradigm Shift in Cancer Immunotherapy: From Enhancement to Normalization

Cited by 1 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Trial watch: local anesthetics in cancer therapy;OncoImmunology;2024-03-17